Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The distinct metabolism between large and small HDL indicates unique origins of human apolipoprotein A4
Allison B. Andraski, … , Masanori Aikawa, Frank M. Sacks
Allison B. Andraski, … , Masanori Aikawa, Frank M. Sacks
Published April 24, 2023
Citation Information: JCI Insight. 2023;8(8):e162481. https://doi.org/10.1172/jci.insight.162481.
View: Text | PDF
Research Article Metabolism

The distinct metabolism between large and small HDL indicates unique origins of human apolipoprotein A4

  • Text
  • PDF
Abstract

Apolipoprotein A4’s (APOA4’s) functions on HDL in humans are not well understood. A unique feature of APOA4 is that it is an intestinal apolipoprotein secreted on HDL and chylomicrons. The goal of this study was to gain a better understanding of the origin and function of APOA4 on HDL by studying its metabolism across 6 HDL sizes. Twelve participants completed a metabolic tracer study. HDL was isolated by APOA1 immunopurification and separated by size. Tracer enrichments for APOA4 and APOA1 were determined by targeted mass spectrometry, and metabolic rates were derived by compartmental modeling. APOA4 metabolism on small HDL (alpha3, prebeta, and very small prebeta) was distinct from that of APOA4 on large HDL (alpha0, 1, 2). APOA4 on small HDL appeared in circulation by 30 minutes and was relatively rapidly catabolized. In contrast, APOA4 on large HDL appeared in circulation later (1–2 hours) and had a much slower catabolism. The unique metabolic profiles of APOA4 on small and large HDL likely indicate that each has a distinct origin and function in humans. This evidence supports the notion that APOA4 on small HDL originates directly from the small intestine while APOA4 on large HDL originates from chylomicron transfer.

Authors

Allison B. Andraski, Sasha A. Singh, Hideyuki Higashi, Lang Ho Lee, Masanori Aikawa, Frank M. Sacks

×

Figure 5

APOA1 metabolism across 6 HDL sizes.

Options: View larger image (or click on image) Download as PowerPoint
APOA1 metabolism across 6 HDL sizes.
(A) APOA1 compartmental model used ...
(A) APOA1 compartmental model used to determine the FCR (pools/d) and PR (mg/kg/d) of APOA1 on each HDL size. Numbers next to arrows represent average flux (mg/kg/d), percentage of total flux, rate of removal (pools/d), and percentage of total protein removal values for participants 1 to 6. (B) Percentage of total APOA1 flux into prebeta and into prebeta-b from the source, delay, and alpha3 compartments. (C) Percentage of total APOA1 removal out of prebeta and out of prebeta-b by each removal pathway (out of the model system, alpha0, alpha1, and alpha2). (D) Percentage of total APOA1 secretion (mg/kg/d) from the source compartment and into alpha0, 1, 2, and 3; prebeta; prebeta-b, and the extravascular delay. APOA1 FCR (E) and PR (F) on each HDL size and in the total model system. The total model system FCR and PR represent the rate of total APOA1 being removed and the total amount of APOA1 entering the HDL system per day, respectively. (B–F) Bar height and error bars represent the mean (±SD) of the 6 participants.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts